MedTrace Logo

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

NCT00168766 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 345

Last updated 2013-09-16

No results posted yet for this study

Summary

The primary objective of this study is to determine whether combination treatment (adding methylprednisolone to Avonex) reduces progression of disability over 4 years compared to Avonex alone. The study will also investigate whether combination therapy has any impact on the incidence of relapse and brain atrophy as measured by MRI.

Conditions

  • Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

Interferon-beta-1a (Avonex) plus methylprednisolone

oral administration given on 3 consecutive days, monthly as described in protocol.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Belgium
  • Denmark
  • Finland
  • Netherlands
  • Norway
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00168766 on ClinicalTrials.gov